BERGEN KASSOFF: Open Payments
NPI 1295420875 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,308 in 54 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $865 · 2025 $1,308
Food & beverage: $1,308
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $348 |
| ABBVIE INC. | 8 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $154 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $119 |
| Ardelyx, Inc. | 5 | $117 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| PFIZER INC. | 3 | $66 |
| Intercept Pharmaceuticals, Inc. | 2 | $48 |
| Novo Nordisk Inc | 2 | $35 |
| Celltrion USA Inc. | 1 | $33 |
Products named: TREMFYA, XIFAXAN, IBSRELA, ENTYVIO, RINVOQ, VOQUEZNA, LINZESS, VIBERZI.
Industry payments across DC — which companies pay providers there.
